Segment Reporting - Summary of the Significant Segment Expenses (Details) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||||||
|---|---|---|---|---|---|---|---|---|
Sep. 30, 2026 |
Jun. 30, 2026 |
Mar. 31, 2026 |
Sep. 30, 2025 |
Jun. 30, 2025 |
Mar. 31, 2025 |
Sep. 30, 2026 |
Sep. 30, 2025 |
|
| Segment Reporting [Line Items] | ||||||||
| Research and development | $ 161,744 | $ 97,219 | $ 414,918 | $ 302,902 | ||||
| Platform and external research and development | 21,464 | 5,769 | 47,046 | 21,399 | ||||
| Personnel related | 32,266 | 22,517 | 89,613 | 62,730 | ||||
| Stock-based compensation | 16,206 | 11,082 | 44,263 | 34,625 | ||||
| Facility-related and other | 14,836 | 9,448 | 39,225 | 26,703 | ||||
| Professional and consulting fees | 12,609 | 4,557 | 30,341 | 15,320 | ||||
| Interest income | (9,767) | (8,476) | (26,312) | (22,202) | ||||
| Interest expense | 5,949 | 2,904 | 14,746 | 2,998 | ||||
| Other expense (income), net | 296 | (279) | 517 | 1,408 | ||||
| Net loss | 193,552 | $ 178,556 | $ 120,854 | 108,041 | $ 110,857 | $ 115,361 | 492,962 | 334,259 |
| DYNE-251 (DMD) | ||||||||
| Segment Reporting [Line Items] | ||||||||
| Research and development | 66,877 | 22,666 | 156,946 | 73,314 | ||||
| DYNE-101 (DM1) | ||||||||
| Segment Reporting [Line Items] | ||||||||
| Research and development | $ 32,816 | $ 37,853 | $ 96,577 | $ 117,964 | ||||
| X | ||||||||||
- Definition Platform and external research and development No definition available.
|
| X | ||||||||||
- Definition Preclinical and platform related No definition available.
|
| X | ||||||||||
- Definition Facility expenses incurred related to gas and oil produced and sold during the reporting period. Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
|
| X | ||||||||||
- Definition Amount of interest expense classified as other. No definition available.
|
| X | ||||||||||
- Definition Amount of interest income earned from interest bearing assets classified as other. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations. No definition available.
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of noncash expense for share-based payment arrangement. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|